Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ZNTLZentalis Pharmaceuticals, Inc.

Nasdaq · CIK 0001725160
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts293

Identity from submissions API

NameZentalis Pharmaceuticals, Inc.
CIK0001725160
TickersZNTL
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN823607803
LEI—
Fiscal year end1231
State of incorporation—
Phone(858) 263-4333
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Zentalis Pharmaceuticals, LLC (2020-01-08T05:00:00.000Z → 2020-04-06T04:00:00.000Z)
  • Zeno Pharma, LLC (2017-12-19T05:00:00.000Z → 2019-09-05T04:00:00.000Z)
Business address
10275 SCIENCE CENTER DRIVE
SUITE 200
SAN DIEGO
CA
92121
CA
Mailing address
10275 SCIENCE CENTER DRIVE
SUITE 200
SAN DIEGO
CA
92121
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

550 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001873515-26-000003 005-91478 261562187 34 26447
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002050709-26-000033 005-91478 261558310 34 81762
2026-11-09 10-Q 10-Q 0001725160-26-000070 001-39263 261536065 34 6555080 1 1
2026-11-09 8-K 8-K 2.02,7.01 0001725160-26-000069 001-39263 261535987 34 5148283 1 1
2026-10-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003868 005-91478 261491707 34 11075
2026-10-01 4 FORM 4 0001628280-26-064317 5618
2026-08-19 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001213900-26-091824 005-91478 261296692 34 10479
2026-08-19 4 xslF345X06/ownership.xml 0001213900-26-091823 9185
2026-08-14 8-K 8-K 8.01,9.01 0001628280-26-057112 001-39263 261281535 34 453247 1 1
2026-08-14 424B5 424B5 0001628280-26-057108 333-286122 261281503 33 573497
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000312069-26-000217 005-91478 261275518 34 6503
2026-08-13 424B5 424B5 0001628280-26-056729 333-286122 261273539 33 603221
2026-08-06 10-Q 10-Q 0001725160-26-000062 001-39263 261249200 34 6414993 1 1
2026-08-06 8-K 8-K 2.02,7.01 0001725160-26-000061 001-39263 261249086 34 5930844 1 1
2026-07-30 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003135 005-91478 261221135 34 11023
2026-06-18 4 FORM 4 0001808098-26-000003 318265
2026-06-18 4 FORM 4 0001838042-26-000003 313499
2026-06-18 4 FORM 4 0001701440-26-000004 345162
2026-06-18 4 FORM 4 0001843119-26-000003 319860
2026-06-18 4 FORM 4 0001356256-26-000005 318266
2026-06-18 8-K 8-K 5.07 0001725160-26-000052 001-39263 261102436 34 177995 1 1
2026-05-27 4 FORM 4 0002018966-26-000005 5295
2026-05-27 3 FORM 3 0002018966-26-000004 343623
2026-05-27 DEFA14A DEFA14A 0001725160-26-000050 001-39263 261026203 34 653879
2026-05-27 8-K 8-K 5.02 0001725160-26-000049 001-39263 261026183 34 163045 1 1
2026-05-21 8-K 8-K 7.01,8.01 0001725160-26-000045 001-39263 261010026 34 381981 1 1
2026-05-12 10-Q 10-Q 0001725160-26-000042 001-39263 26968639 34 5929020 1 1
2026-05-12 8-K 8-K 2.02,7.01 0001725160-26-000041 001-39263 26968568 34 5928923 1 1
2026-05-05 8-K 8-K 7.01,8.01 0001725160-26-000033 001-39263 26940514 34 296774 1 1
2026-04-30 DEFA14A DEFA14A 0001725160-26-000028 001-39263 26925329 34 1256976
2026-04-30 DEF 14A DEF 14A 0001725160-26-000027 001-39263 26925099 34 3691532 1 1
2026-04-30 ARS ARS 0001725160-26-000026 001-39263 26924932 34 20597548
2026-04-17 8-K 8-K 7.01 0001725160-26-000020 001-39263 26871172 34 8698773 1 1
2026-04-09 8-K 8-K 7.01,8.01 0001725160-26-000017 001-39263 26849864 34 6764114 1 1
2026-03-26 10-K 10-K 0001725160-26-000014 001-39263 26799017 34 10446795 1 1
2026-03-26 8-K 8-K 2.02,9.01 0001725160-26-000010 001-39263 26798608 34 354062 1 1
2026-03-03 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002050709-26-000011 005-91478 26713930 34 80885
2026-02-10 4 FORM 4 0001838041-26-000004 6467
2026-02-10 4 FORM 4 0002018766-26-000006 8044
2026-02-10 4 FORM 4 0001500189-26-000004 6503
2026-02-04 4 FORM 4 0002018766-26-000004 6622
2026-01-09 4 FORM 4 0002018766-26-000002 315325
2026-01-09 4 FORM 4 0001664928-26-000003 5581
2026-01-09 4 FORM 4 0001838041-26-000002 314559
2026-01-09 4 FORM 4 0001500189-26-000002 313104
2026-01-09 8-K 8-K 7.01,8.01 0001725160-26-000003 001-39263 26523980 34 6771976 1 1
2026-01-08 4 xslF345X05/ownership.xml 0001213900-26-002567 8926
2026-01-08 3 OWNERSHIP DOCUMENT 0001213900-26-002566 8739
2026-01-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-26-001456 005-91478 26509092 34 11142
2026-01-02 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000902664-26-000024 005-91478 26502478 34 9706
2025-12-30 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001873515-25-000004 005-91478 251614379 34 22591
2025-12-15 4 xslF345X05/ownership.xml 0000902664-25-005288 7940
2025-12-15 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000902664-25-005287 005-91478 251572501 34 10101
2025-12-15 8-K 8-K 5.02,8.01 0001725160-25-000164 001-39263 251572355 34 170605 1 1
2025-11-12 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000312069-25-000592 005-91478 251472663 34 6378
2025-11-10 10-Q 10-Q 0001725160-25-000161 001-39263 251466400 34 6988150 1 1
2025-11-10 8-K 8-K 2.02,7.01,9.01 0001725160-25-000159 001-39263 251466290 34 6657710 1 1
2025-10-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-099251 005-91478 251391679 34 15771
2025-10-01 4 FORM 4 0001664928-25-000008 5690
2025-09-22 3 FORM 3 0001664928-25-000006 321643
2025-08-26 8-K 8-K 5.02,7.01,9.01 0001725160-25-000154 001-39263 251257671 34 284110 1 1
2025-08-06 10-Q 10-Q 0001725160-25-000149 001-39263 251189732 34 6995609 1 1
2025-08-06 8-K 8-K 2.02,7.01 0001725160-25-000147 001-39263 251189590 34 6648942 1 1
2025-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002526 005-91478 251128504 34 11029
2025-06-18 4 FORM 4 0001725160-25-000137 5258
2025-06-18 4 FORM 4 0001725160-25-000135 5231
2025-06-18 4 FORM 4 0001725160-25-000133 5267
2025-06-18 4 FORM 4 0001725160-25-000131 5248
2025-06-18 4 FORM 4 0001725160-25-000129 5254
2025-06-18 8-K 8-K 5.07 0001725160-25-000127 001-39263 251056994 34 180462 1 1
2025-06-02 8-K 8-K 7.01,9.01 0001725160-25-000119 001-39263 251012990 34 3840660 1 1
2025-05-23 DEFA14A DEFA14A 0001725160-25-000112 001-39263 25982603 34 39263
2025-05-20 8-K 8-K 7.01,9.01 0001725160-25-000108 001-39263 25966063 34 163174 1 1
2025-05-14 S-8 S-8 0001725160-25-000106 333-287263 25945756 33 376929
2025-05-14 10-Q 10-Q 0001725160-25-000105 001-39263 25945644 34 6816342 1 1
2025-05-14 8-K 8-K 2.02,9.01 0001725160-25-000104 001-39263 25945521 34 344648 1 1
2025-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-003116 005-91478 25944993 34 11413
2025-05-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-003101 005-91478 25941681 34 11366
2025-04-30 4 FORM 4 0001725160-25-000094 4733
2025-04-30 DEFA14A DEFA14A 0001725160-25-000093 001-39263 25895373 34 1241911
2025-04-30 DEF 14A DEF 14A 0001725160-25-000092 001-39263 25895150 34 3388969 1 1
2025-04-30 ARS ARS 0001725160-25-000091 001-39263 25894906 34 21103616
2025-04-28 8-K 8-K 7.01,9.01 0001725160-25-000082 001-39263 25875818 34 15655351 1 1
2025-04-04 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000989 333-286122 25816231 33 1953
2025-04-02 CORRESP filename1.htm 0001725160-25-000073 10482
2025-04-01 UPLOAD filename1.pdf 0000000000-25-003491 333-286122 40344
2025-03-26 8-K 8-K 2.02,9.01 0001725160-25-000070 001-39263 25773552 34 355175 1 1
2025-03-26 S-3 S-3 0001725160-25-000069 333-286122 25773519 33 1445869
2025-03-26 10-K 10-K 0001725160-25-000067 001-39263 25773286 34 11591632 1 1
2025-03-17 8-K 8-K 7.01,9.01 0001628280-25-012899 001-39263 25742266 34 2484330 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-001015 005-91478 25625554 34 15231
2025-02-12 4 FORM 4 0001725160-25-000047 4782
2025-02-11 144 xsl144X01/primary_doc.xml 0001725160-25-000045 001-39263 25611511 33 5434
2025-02-05 4 FORM 4 0001725160-25-000043 9066
2025-02-05 4 FORM 4 0001725160-25-000041 9066
2025-02-05 4 FORM 4 0001725160-25-000040 8982
2025-02-05 4 FORM 4 0001725160-25-000037 7395
2025-02-05 4 FORM 4 0001725160-25-000036 7424
2025-02-04 4 FORM 4 0001725160-25-000030 4706
2025-02-04 4 FORM 4 0001725160-25-000029 4743
2025-02-04 4 FORM 4 0001725160-25-000028 4811
2025-02-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-009101 005-91478 25588150 34 15142
2025-02-03 144 xsl144X01/primary_doc.xml 0001725160-25-000022 001-39263 25584318 33 5297
2025-02-03 144 xsl144X01/primary_doc.xml 0001725160-25-000020 001-39263 25584313 33 4628
2025-02-03 144 xsl144X01/primary_doc.xml 0001725160-25-000018 001-39263 25584312 33 4941
2025-01-31 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002053359-25-000002 005-91478 25577181 34 9519
2025-01-31 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000275 005-91478 25576429 34 6469
2025-01-29 8-K 8-K 7.01,8.01,9.01 0001725160-25-000013 001-39263 25566983 34 7552538 1 1
2025-01-28 8-K 8-K 2.05,7.01,8.01,9.01 0001725160-25-000006 001-39263 25564187 34 302042 1 1
2025-01-22 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001689655-25-000004 005-91478 25544147 34 9501
2025-01-08 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001689655-25-000001 005-91478 25519644 34 9531
2025-01-03 4 FORM 4 0001725160-25-000002 5081
2024-12-19 8-K/A 8-K/A 5.02 0001725160-24-000193 001-39263 241563261 34 177169 1 1
2024-12-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001689655-24-000020 005-91478 241537756 34 9419
2024-12-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-24-002990 005-91478 241531243 34 11592
2024-12-03 4 FORM 4 0001725160-24-000190 5771
2024-12-03 4 FORM 4 0001725160-24-000189 5760
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-118978 005-91478 241462753 34 136915
2024-11-13 4 FORM 4 0001725160-24-000186 5157
2024-11-13 3 FORM 3 0001725160-24-000185 342463
2024-11-13 3 FORM 3 0001725160-24-000184 343046
2024-11-13 3 FORM 3 0001725160-24-000183 341595
2024-11-13 8-K 8-K 5.02,7.01,9.01 0001725160-24-000177 001-39263 241451278 34 235437 1 1
2024-11-12 SC 13G/A UnitedStates_13G__ZentalisPh.txt 0000932471-24-001300 005-91478 241450347 34 6771
2024-11-12 10-Q 10-Q 0001725160-24-000173 001-39263 241447722 34 11267560 1 1
2024-11-06 SC 13G/A SC 13G/A 0001580642-24-006742 005-91478 241430345 34 57746
2024-11-04 SC 13G/A UnitedStates_13G__ZentalisPh.txt 0000932471-24-000785 005-91478 241422622 34 5808
2024-10-31 144 xsl144X01/primary_doc.xml 0001725160-24-000168 001-39263 241416728 33 4613
2024-10-18 SC 13G/A Zentalis_Pharma_Inc.htm 0000093751-24-000899 005-91478 241379776 34 56063
2024-10-17 UPLOAD filename1.pdf 0000000000-24-011665 001-39263 39920
2024-10-10 CORRESP filename1.htm 0001725160-24-000166 126011
2024-10-07 SC 13G/A filing.txt 0000315066-24-002028 005-91478 241356669 34 8478
2024-10-04 4 FORM 4 0001725160-24-000163 5160
2024-09-16 8-K 8-K 7.01,8.01,9.01 0001725160-24-000161 001-39263 241299302 34 290208 1 1
2024-09-12 UPLOAD filename1.pdf 0000000000-24-010304 001-39263 44144
2024-08-09 10-Q 10-Q 0001725160-24-000158 001-39263 241190377 34 11591161 1 1
2024-08-09 8-K 8-K 2.02,9.01 0001725160-24-000157 001-39263 241190371 34 344470 1 1
2024-06-21 4 FORM 4 0001725160-24-000145 354520
2024-06-21 4 FORM 4 0001725160-24-000143 355357
2024-06-21 4 FORM 4 0001725160-24-000141 349922
2024-06-21 8-K 8-K 5.07 0001725160-24-000140 001-39263 241061311 34 188893 1 1
2024-06-03 8-K 8-K 7.01,9.01 0001725160-24-000131 001-39263 241011960 34 9376151 1 1
2024-05-31 144 xsl144X01/primary_doc.xml 0001725160-24-000129 001-39263 241011392 33 4871
2024-05-31 4 FORM 4 0001725160-24-000127 327961
2024-05-29 4 FORM 4 0001725160-24-000123 5092
2024-05-29 3 FORM 3 0001725160-24-000122 329016
2024-05-29 DEFA14A DEFA14A 0001725160-24-000121 001-39263 24994005 34 131015
2024-05-29 8-K 8-K 5.02 0001725160-24-000120 001-39263 24993988 34 159673 1 1
2024-05-09 144 xsl144X01/primary_doc.xml 0001725160-24-000113 001-39263 24932517 33 4650
2024-05-09 4 FORM 4 0001725160-24-000111 355217
2024-05-07 10-Q 10-Q 0001725160-24-000107 001-39263 24919562 34 6535156 1 1
2024-05-07 8-K 8-K 2.02,9.01 0001725160-24-000106 001-39263 24919550 34 355096 1 1
2024-04-29 DEFA14A DEFA14A 0001725160-24-000097 001-39263 24891777 34 1234026
2024-04-29 DEF 14A DEF 14A 0001725160-24-000096 001-39263 24891640 34 5201838 1 1
2024-04-29 ARS ARS 0001725160-24-000095 001-39263 24891522 34 22478354
2024-04-11 3 FORM 3 0001725160-24-000089 350621
2024-04-11 8-K 8-K 5.02 0001725160-24-000087 001-39263 24837104 34 163565 1 1
2024-04-09 8-K 8-K 7.01,9.01 0001725160-24-000082 001-39263 24833109 34 8458035 1 1
2024-02-29 S-8 S-8 0001628280-24-008062 333-277550 24705180 33 377097
2024-02-29 S-3ASR S-3ASR 0001628280-24-008056 333-277545 24705089 33 1432861
2024-02-27 10-K 10-K 0001725160-24-000080 001-39263 24681940 34 49627536 1 1
2024-02-27 8-K 8-K 2.02,9.01 0001725160-24-000079 001-39263 24681923 34 363276 1 1
2024-02-15 8-K 8-K 5.03,9.01 0001725160-24-000057 001-39263 24643942 34 529112 1 1
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023930 005-91478 24639965 34 138021
2024-02-13 SC 13G/A d10977822_13g-a.htm 0000919574-24-001194 005-91478 24631207 34 162610
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-022352 005-91478 24629970 34 13240
2024-02-12 144 xsl144X01/primary_doc.xml 0001725160-24-000049 001-39263 24622206 33 5447
2024-02-12 144 xsl144X01/primary_doc.xml 0001725160-24-000047 001-39263 24622205 33 5410
2024-02-12 144 xsl144X01/primary_doc.xml 0001725160-24-000045 001-39263 24622203 33 5460
2024-02-12 4 FORM 4 0001725160-24-000043 5481
2024-02-12 4 FORM 4 0001725160-24-000041 5461
2024-02-09 SC 13G/A SEC SCHEDULE 13G 0001422848-24-000149 005-91478 24616631 34 18594
2024-02-09 SC 13G/A filing.txt 0000315066-24-001568 005-91478 24612622 34 8425
2024-02-09 SC 13G/A SEC SCHEDULE 13G 0000902219-24-000276 005-91478 24611404 34 33142
2024-02-05 4 FORM 4 0001725160-24-000036 7839
2024-02-05 4 FORM 4 0001725160-24-000034 9645
2024-02-05 4 FORM 4 0001725160-24-000032 11935
2024-02-05 4 FORM 4 0001725160-24-000030 9428
2024-02-05 4 FORM 4 0001725160-24-000028 9443
2024-02-05 4 FORM 4 0001725160-24-000026 8948
2024-02-02 144 xsl144X01/primary_doc.xml 0001725160-24-000024 001-39263 24593709 33 4623
2024-02-02 144 xsl144X01/primary_doc.xml 0001725160-24-000023 001-39263 24593708 33 4558
2024-02-02 144 xsl144X01/primary_doc.xml 0001725160-24-000022 001-39263 24593706 33 4804
2024-02-02 144 xsl144X01/primary_doc.xml 0001725160-24-000021 001-39263 24593704 33 4839
2024-02-02 144 xsl144X01/primary_doc.xml 0001725160-24-000020 001-39263 24593703 33 4801
2024-02-02 144 xsl144X01/primary_doc.xml 0001725160-24-000019 001-39263 24593701 33 4852
2024-01-29 SC 13G/A us98943l1070_012924.txt 0001086364-24-005115 005-91478 24573094 34 13745
2024-01-25 SC 13G/A Zentalis_Pharma_Inc.txt 0000093751-24-000199 005-91478 24558601 34 8664
2024-01-25 8-K 8-K 3.01,5.02,7.01,9.01 0001725160-24-000012 001-39263 24558556 34 218109 1 1
2024-01-08 8-K 8-K 7.01,8.01,9.01 0001725160-24-000007 001-39263 24518285 34 228654 1 1
2024-01-03 4 FORM 4 0001725160-24-000004 7771
2024-01-03 3 FORM 3 0001725160-24-000003 224622
2023-12-21 4 FORM 4 0001725160-23-000203 7048
2023-12-11 SC 13G/A SC 13G/A 0001580642-23-006644 005-91478 231478945 34 57430
2023-11-17 SC 13G SC 13G 0001104659-23-119603 005-91478 231419878 34 142920
2023-11-13 4 FORM 4 0001725160-23-000201 5094
2023-11-13 4 FORM 4 0001725160-23-000200 4678
2023-11-06 10-Q 10-Q 0001725160-23-000196 001-39263 231378608 34 7122232 1 1
2023-11-06 8-K 8-K 2.02,7.01,9.01 0001725160-23-000195 001-39263 231378601 34 8820346 1 1
2023-10-10 SC 13G SC 13G 0001580642-23-005465 005-91478 231317800 34 59764
2023-10-06 4 FORM 4 0001725160-23-000181 7265
2023-10-06 4 FORM 4 0001725160-23-000180 9260
2023-10-06 4 FORM 4 0001725160-23-000179 7516
2023-10-06 8-K 8-K 5.02 0001725160-23-000178 001-39263 231314798 34 158742 1 1
2023-10-04 144 xsl144X01/primary_doc.xml 0001725160-23-000172 001-39263 231309566 33 5088
2023-10-04 144 xsl144X01/primary_doc.xml 0001725160-23-000170 001-39263 231309561 33 5118
2023-10-04 144 xsl144X01/primary_doc.xml 0001725160-23-000168 001-39263 231309557 33 5089
2023-09-13 4 FORM 4 0001725160-23-000162 5249
2023-09-13 8-K 8-K 7.01,9.01 0001725160-23-000161 001-39263 231251588 34 6844418 1 1
2023-09-11 144 xsl144X01/primary_doc.xml 0001950047-23-003872 001-39263 231247824 33 4826
2023-08-09 8-K 8-K 7.01,9.01 0001725160-23-000157 001-39263 231155344 34 7440708 1 1
2023-08-09 10-Q 10-Q 0001725160-23-000155 001-39263 231153332 34 7370977 1 1
2023-08-09 8-K 8-K 2.02,9.01 0001725160-23-000154 001-39263 231153317 34 323772 1 1
2023-06-20 4 xslF345X04/ownership.xml 0000902664-23-003642 7728
2023-06-20 SC 13D/A ZENTALIS PHARMACEUTICALS, INC. 0000902664-23-003640 005-91478 231025567 34 51294
2023-06-16 8-K 8-K 5.03,5.07,9.01 0001725160-23-000148 001-39263 231022306 34 216378 1 1
2023-06-16 4 FORM 4 0001725160-23-000146 5133
2023-06-16 4 FORM 4 0001725160-23-000143 5113
2023-06-16 4 FORM 4 0001725160-23-000141 5096
2023-06-15 8-K 8-K 8.01,9.01 0001628280-23-022240 001-39263 231017674 34 557463 1 1
2023-06-15 424B5 424B5 0001628280-23-022224 333-255769 231017465 33 585378
2023-06-15 FWP FWP 0001628280-23-022129 333-255769 231015938 34 134206
2023-06-15 8-K 8-K 8.01 0001725160-23-000137 001-39263 231015880 34 178784 1 1
2023-06-06 8-K 8-K 7.01,8.01,9.01 0001725160-23-000131 001-39263 23995036 34 15849385 1 1
2023-06-05 8-K 8-K 7.01,8.01,9.01 0001725160-23-000129 001-39263 23992035 34 920530 1 1
2023-05-31 144 xsl144X01/primary_doc.xml 0001725160-23-000126 001-39263 23982859 33 5146
2023-05-31 4 FORM 4 0001725160-23-000125 6945
2023-05-31 4 FORM 4 0001725160-23-000124 7296
2023-05-31 144 xsl144X01/primary_doc.xml 0001950047-23-001083 001-39263 23981495 33 4883
2023-05-26 8-K 8-K 7.01,8.01,9.01 0001725160-23-000119 001-39263 23966142 34 263405 1 1
2023-05-10 4 FORM 4 0001725160-23-000116 5152
2023-05-10 3 FORM 3 0001725160-23-000115 479906
2023-05-10 DEFA14A DEFA14A 0001725160-23-000114 001-39263 23904302 34 76267
2023-05-10 10-Q 10-Q 0001725160-23-000113 001-39263 23904295 34 6463594 1 1
2023-05-10 8-K 8-K 2.02,9.01 0001725160-23-000112 001-39263 23904287 34 264795 1 1
2023-04-28 DEFA14A DEFA14A 0001725160-23-000082 001-39263 23867338 34 1299584
2023-04-28 ARS ARS 0001725160-23-000080 001-39263 23867314 34 2433713
2023-04-28 DEF 14A DEF 14A 0001725160-23-000078 001-39263 23867210 34 3559214 1 1
2023-04-26 8-K 8-K 7.01,8.01,9.01 0001725160-23-000073 001-39263 23850621 34 247974 1 1
2023-04-18 PRE 14A PRE 14A 0001725160-23-000068 001-39263 23827187 34 3483167 1 1
2023-04-17 8-K 8-K 7.01,8.01,9.01 0001725160-23-000063 001-39263 23823006 34 8627678 1 1
2023-03-10 8-K 8-K 7.01 0001725160-23-000057 001-39263 23724184 34 179921 1 1
2023-03-10 SC 13G/A SC 13G/A 0001104659-23-030717 005-91478 23721239 34 31060
2023-03-09 8-K 8-K 1.01 0001725160-23-000053 001-39263 23720336 34 180441 1 1
2023-03-02 4 FORM 4 0001725160-23-000050 7369
2023-03-01 10-K 10-K 0001725160-23-000048 001-39263 23689690 34 12386155 1 1
2023-03-01 8-K 8-K 2.02,7.01 0001725160-23-000047 001-39263 23689680 34 8320549 1 1
2023-02-14 4 FORM 4 0001725160-23-000035 7444
2023-02-14 4 FORM 4 0001725160-23-000033 7425
2023-02-14 4 FORM 4 0001725160-23-000031 9432
2023-02-14 SC 13G/A zntl13gadec22.txt 0000080255-23-002712 005-91478 34 7202
2023-02-14 SC 13G/A d9942383_13g-a.htm 0000919574-23-001460 005-91478 23625207 34 166771
2023-02-14 SC 13G sch13ga.htm 0000929638-23-000483 005-91478 23624360 34 99906
2023-02-13 SC 13G SEC SCHEDULE 13G 0001562230-23-000093 005-91478 23618029 34 18517
2023-02-13 3 FORM 3 0001725160-23-000029 496641
2023-02-13 8-K 8-K 5.02,9.01 0001725160-23-000028 001-39263 23614644 34 7788451 1 1
2023-02-09 SC 13G/A filing.txt 0000315066-23-002153 005-91478 23605175 34 8338
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-017354 005-91478 23604636 34 13133
2023-02-07 SC 13G Zentalis_Pharma_Inc.txt 0000093751-23-000312 005-91478 23593932 34 8599
2023-02-06 4 FORM 4 0001725160-23-000022 7168
2023-02-06 SC 13G SEC SCHEDULE 13G 0000846087-23-000198 005-91478 23590250 34 37641
2023-02-01 4 FORM 4 0001725160-23-000020 10584
2023-02-01 4 FORM 4 0001725160-23-000019 7112
2023-02-01 4 FORM 4 0001725160-23-000018 7168
2023-02-01 4 FORM 4 0001725160-23-000017 7330
2023-02-01 4 FORM 4 0001725160-23-000016 7052
2023-02-01 4 FORM 4 0001725160-23-000015 7107
2023-02-01 SC 13G/A us98943l1070_020123.txt 0001306550-23-006402 005-91478 23577614 34 13523
2023-01-18 4 FORM 4 0001725160-23-000008 7168
2023-01-09 8-K 8-K 7.01,9.01 0001725160-23-000006 001-39263 23516495 34 8800095 1 1
2023-01-05 4 FORM 4 0001725160-23-000002 7168
2022-11-15 4 FORM 4 0001725160-22-000202 7167
2022-11-09 10-Q 10-Q 0001725160-22-000200 001-39263 221370629 34 7120198 1 1
2022-11-09 8-K 8-K 2.02,7.01 0001725160-22-000199 001-39263 221370613 34 8706896 1 1
2022-11-08 4 FORM 4 0001725160-22-000194 9040
2022-10-31 10-K/A 10-K/A 0001725160-22-000187 001-39263 221347224 34 341223 1 1
2022-10-17 4 FORM 4 0001725160-22-000184 5302
2022-10-07 4 FORM 4 0001725160-22-000182 9039
2022-10-03 4 FORM 4 0001725160-22-000180 5260
2022-10-03 4 FORM 4 0001725160-22-000179 9469
2022-10-03 4 FORM 4 0001725160-22-000178 10166
2022-10-03 3 FORM 3 0001725160-22-000177 498952
2022-09-27 8-K 8-K 5.02 0001725160-22-000170 001-39263 221271175 34 175806 1 1
2022-09-16 4 FORM 4 0001725160-22-000167 10908
2022-09-12 4 FORM 4 0001725160-22-000165 5039
2022-09-12 3 FORM 3 0001725160-22-000164 476051
2022-09-12 8-K 8-K 5.02 0001725160-22-000163 001-39263 221237359 34 180863 1 1
2022-08-12 4 FORM 4 0001725160-22-000159 6840
2022-08-09 S-8 S-8 0001725160-22-000157 333-266702 221148614 33 202228
2022-08-09 10-Q 10-Q 0001725160-22-000155 001-39263 221148449 34 6393023 1 1
2022-08-09 8-K 8-K 2.02,7.01 0001725160-22-000154 001-39263 221148304 34 7335579 1 1
2022-08-01 4 FORM 4 0001725160-22-000142 5794
2022-08-01 3 FORM 3 0001725160-22-000141 391887
2022-07-22 8-K 8-K 5.02,9.01 0001725160-22-000138 001-39263 221100112 34 452307 1 1
2022-07-20 4 FORM 4 0001725160-22-000135 6854
2022-07-14 4 FORM 4 0001725160-22-000133 9355
2022-07-06 4 FORM 4 0001725160-22-000131 7325
2022-06-29 UPLOAD filename1.pdf 0000000000-22-006963 39801
2022-06-27 8-K 8-K 5.02 0001725160-22-000129 001-39263 221041573 34 176148 1 1
2022-06-22 CORRESP filename1.htm 0001725160-22-000125 41835
2022-06-13 8-K 8-K 5.07 0001725160-22-000123 001-39263 221012361 34 195686 1 1
2022-06-10 4 FORM 4 0001725160-22-000121 5105
2022-06-10 4 FORM 4 0001725160-22-000120 5081
2022-06-09 UPLOAD filename1.pdf 0000000000-22-006245 44798
2022-06-03 3 xslF345X02/ownership.xml 0000902664-22-003161 6766
2022-06-03 SC 13D ZENTALIS PHARMACEUTICALS, INC. 0000902664-22-003160 005-91478 22993262 34 68112
2022-05-31 4 FORM 4 0001725160-22-000116 7203
2022-05-31 DEFA14A DEFA14A 0001725160-22-000115 001-39263 22983157 34 46688
2022-05-31 8-K 8-K 5.02,9.01 0001725160-22-000114 001-39263 22983151 34 336078 1 1
2022-05-26 CORRESP filename1.htm 0001725160-22-000107 46867
2022-05-24 8-K 8-K 3.01 0001725160-22-000104 001-39263 22958170 34 178249 1 1
2022-05-20 4 FORM 4 0001725160-22-000100 7787
2022-05-18 DEFA14A DEFA14A 0001725160-22-000097 001-39263 22939045 34 50185
2022-05-16 8-K 8-K 8.01,9.01 0001628280-22-014546 001-39263 22930982 34 590376 1 1
2022-05-16 424B5 424B5 0001628280-22-014544 333-255769 22930955 33 485612
2022-05-16 8-K FORM 8-K 5.02,9.01 0001193125-22-150883 001-39263 22925452 34 339898 1 1
2022-05-12 UPLOAD filename1.pdf 0000000000-22-005228 47610
2022-05-05 10-Q 10-Q 0001725160-22-000093 001-39263 22894012 34 5635190 1 1
2022-05-05 8-K 8-K 2.02,9.01 0001725160-22-000092 001-39263 22893987 34 249126 1 1
2022-04-28 DEFA14A DEFA14A 0001725160-22-000083 001-39263 22866776 34 291790
2022-04-28 DEF 14A DEF 14A 0001725160-22-000082 001-39263 22866679 34 1045587
2022-04-27 424B5 424B5 0001628280-22-010798 333-255769 22859730 33 516701
2022-04-27 8-K 8-K 8.01,9.01 0001628280-22-010794 001-39263 22859615 34 497102 1 1
2022-04-13 4 FORM 4 0001725160-22-000078 10916
2022-04-11 8-K 8-K 7.01,8.01,9.01 0001725160-22-000076 001-39263 22820113 34 214342 1 1
2022-04-11 8-K/A 8-K 7.01,9.01 0001725160-22-000075 001-39263 22820062 34 185055 1 1
2022-04-08 8-K 8-K 7.01,8.01 0001725160-22-000072 001-39263 22817782 34 8818989 1 1
2022-04-05 4 FORM 4 0001725160-22-000069 12888
2022-04-05 4 FORM 4 0001725160-22-000068 12509
2022-04-05 4 FORM 4 0001725160-22-000067 10447
2022-03-21 4 FORM 4 0001725160-22-000063 9355
2022-03-16 4 FORM 4 0001725160-22-000061 8579
2022-03-10 4 FORM 4 0001725160-22-000059 11387
2022-03-08 4 FORM 4 0001725160-22-000057 7176
2022-03-03 4 FORM 4 0001725160-22-000055 14844
2022-02-24 10-K 10-K 0001725160-22-000053 001-39263 22666498 34 15587097 1 1
2022-02-24 8-K 8-K 2.02,9.01 0001725160-22-000052 001-39263 22666480 34 252464 1 1
2022-02-23 4 FORM 4 0001725160-22-000048 13417
2022-02-23 4 FORM 4 0001725160-22-000047 7280
2022-02-15 4 FORM 4 0001725160-22-000038 9045
2022-02-14 4 FORM 4 0001725160-22-000036 22554
2022-02-14 4 FORM 4 0001725160-22-000035 11148
2022-02-14 4 FORM 4 0001725160-22-000034 11126
2022-02-14 4 FORM 4 0001725160-22-000033 7124
2022-02-14 4 FORM 4 0001725160-22-000032 14763
2022-02-14 4 FORM 4 0001725160-22-000031 15024
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-023123 005-91478 22634485 34 68937
2022-02-14 SC 13G/A SC 13G/A 0001140361-22-005360 005-91478 22634212 34 279002
2022-02-14 SC 13G zntl13gdec21.txt 0000080255-22-002228 005-91478 34 6968
2022-02-14 SC 13G AMENDMENT NO. 1 0000929638-22-000451 005-91478 22627849 34 100262
2022-02-14 SC 13G/A ZENTALIS PHARMACEUTICALS, INC. 0000902664-22-001676 005-91478 22627816 34 64204
2022-02-10 SC 13G/A SC 13G/A 0001725160-22-000024 005-91478 22615190 34 45939
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-018953 005-91478 22611269 34 13128
2022-02-09 SC 13G/A filing.txt 0000315066-22-001263 005-91478 22604697 34 8626
2022-02-07 4 FORM 4 0001725160-22-000019 9046
2022-02-03 4 FORM 4 0001725160-22-000017 18117
2022-02-03 SC 13G/A us98943l1070_020322.txt 0000834237-22-006439 005-91478 22589225 34 13552
2022-02-01 SC 13G d9169041_13-g.htm 0000919574-22-000577 005-91478 22578643 34 166732
2022-01-20 4 FORM 4 0001725160-22-000015 30805
2022-01-20 4 FORM 4 0001725160-22-000014 11386
2022-01-19 4 FORM 4 0001725160-22-000011 10914
2022-01-11 4 FORM 4 0001725160-22-000009 14315
2022-01-05 4 FORM 4 0001725160-22-000006 27579
2022-01-05 4 FORM 4 0001725160-22-000005 8584
2022-01-05 4 FORM 4 0001725160-22-000004 16093
2021-12-21 4 FORM 4 0001725160-21-000244 13467
2021-12-17 4/A FORM 4/A 0001725160-21-000242 8184
2021-12-16 4 FORM 4 0001725160-21-000240 18435
2021-12-13 4 FORM 4 0001725160-21-000238 13462
2021-12-07 4/A FORM 4/A 0001725160-21-000236 6267
2021-12-07 4 FORM 4 0001725160-21-000235 4889
2021-12-02 4 FORM 4 0001725160-21-000232 37368
2021-12-02 4 FORM 4 0001725160-21-000231 8588
2021-11-23 4 FORM 4 0001725160-21-000228 6907
2021-11-17 8-K 8-K 8.01 0001725160-21-000226 001-39263 211421504 34 181955 1 1
2021-11-16 4 FORM 4 0001725160-21-000224 9092
2021-11-12 4 FORM 4 0001725160-21-000222 8736
2021-11-10 10-Q 10-Q 0001725160-21-000220 001-39263 211394460 34 13979179 1 1
2021-11-10 8-K 8-K 2.02,9.01 0001725160-21-000219 001-39263 211394454 34 268932 1 1
2021-11-05 4 FORM 4 0001725160-21-000213 9092
2021-11-02 4 FORM 4 0001725160-21-000211 19238
2021-11-02 4 FORM 4 0001725160-21-000210 8588
2021-10-27 4 FORM 4 0001725160-21-000207 8592
2021-10-27 4 FORM 4 0001725160-21-000206 14461
2021-10-04 4 FORM 4 0001725160-21-000201 10961
2021-10-04 4 FORM 4 0001725160-21-000200 15807
2021-10-04 4 FORM 4 0001725160-21-000199 4906
2021-10-04 4 FORM 4 0001725160-21-000198 11294
2021-10-04 4 FORM 4 0001725160-21-000197 8667
2021-09-02 4 FORM 4 0001725160-21-000191 7224
2021-09-02 4 FORM 4 0001725160-21-000190 11762
2021-09-02 4 FORM 4 0001725160-21-000189 10726
2021-08-20 4 FORM 4 0001725160-21-000185 7016
2021-08-12 10-Q 10-Q 0001725160-21-000183 001-39263 211165523 34 7291882 1 1
2021-08-12 8-K 8-K 2.02 0001725160-21-000181 001-39263 211165517 34 269968 1 1
2021-08-03 4 FORM 4 0001725160-21-000176 19238
2021-08-03 4 FORM 4 0001725160-21-000175 12761
2021-08-03 4 FORM 4 0001725160-21-000174 10961
2021-07-08 4 FORM 4 0001725160-21-000170 17451
2021-07-08 4 FORM 4 0001725160-21-000169 20070

Latest XBRL company facts

One latest value per concept from companyfacts (293 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 98.27M 2026-11-04 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
dei EntityPublicFloat Entity Public Float USD 66.90M 2025-06-30 2025 FY 10-K 2026-03-26 0001725160-26-000014
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 212,506 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001725160-26-000027
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.44M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001725160-26-000027
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 7 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001725160-26-000027
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 5.33M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 423,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 175,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 27.53M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 27.03M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 359,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 3.22M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -495,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.50B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 9.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 9.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2020-12-31 2020 FY 10-K 2021-03-25 0001725160-21-000075
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 18.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AssetAcquisitionContingentConsiderationLiability AssetAcquisitionContingentConsiderationLiability USD 500,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AssetAcquisitionContingentConsiderationLiabilityCurrent AssetAcquisitionContingentConsiderationLiabilityCurrent USD 500,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap Assets Assets USD 270.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AssetsCurrent Assets, Current USD 237.27M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 214.47M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 495,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 205.36M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss USD 15,000 2020-06-30 2020 Q2 10-Q 2020-08-13 0001725160-20-000016
us-gaap AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five USD 27.92M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value USD 204.86M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 204.86M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 204.86M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 24.03M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 9.60M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 26.66M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -11.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CashDivestedFromDeconsolidation Cash Divested from Deconsolidation USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 250.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 98.26M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 98.26M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap CommonStockValue Common Stock, Value, Issued USD 98,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -107.14M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest USD -137.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 63,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 391,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 328,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 0 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0001725160-22-000155
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss USD 4,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions security 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss USD 495,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions security 32 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 495,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions security 32 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DeconsolidationGainOrLossAmount Deconsolidation, Gain (Loss), Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 716,000 2021-06-30 2021 Q2 10-Q 2021-08-12 0001725160-21-000183
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 51,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredIncomeTaxAssetsNet Deferred Income Tax Assets, Net USD 51,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DeferredIncomeTaxesAndTaxCredits Deferred Income Taxes and Tax Credits USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 51,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 7.61M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 0 2023-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 9.45M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 289.64M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 72.12M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 51,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 7.67M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 145.81M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 28,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 41.55M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation USD 1.90M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 9.07M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 322,000 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses USD 2.50M 2021-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 281.98M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 853,000 2022-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs USD 0 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates Deferred Tax Liabilities, Investment in Noncontrolled Affiliates USD 0 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 6.45M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 675,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 487,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 1.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 456,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap DueFromRelatedPartiesCurrent Due from Related Parties, Current USD 7.91M 2023-03-31 2023 Q1 10-Q 2023-05-10 0001725160-23-000113
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.41 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.24 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-17 0001725160-21-000129
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.41 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.193 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount USD -44,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.008 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.037 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.002 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 11.29M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.068 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.027 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 7.39M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap EquityMethodInvestments Equity Method Investments USD 0 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap EquitySecuritiesFvNi Equity Securities, FV-NI USD 0 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EquitySecuritiesFvNiCurrentAndNoncurrent EquitySecuritiesFvNiCurrentAndNoncurrent USD 19.17M 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap EquitySecuritiesFvNiGainLoss Equity Securities, FV-NI, Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap EquitySecuritiesFvNiRealizedGainLoss Equity Securities, FV-NI, Realized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap EquitySecuritiesFvNiUnrealizedGainLoss Equity Securities, FV-NI, Unrealized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap FiniteLivedIntangibleAssetsNet Finite-Lived Intangible Assets, Net USD 0 2021-09-30 2021 Q3 10-Q 2021-11-10 0001725160-21-000220
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 27.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap Goodwill Goodwill USD 0 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 176.94M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ImpairmentOfIntangibleAssetsExcludingGoodwill Impairment of Intangible Assets (Excluding Goodwill) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-lived USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -136.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -106.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 368,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -136.62M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeLossFromEquityMethodInvestments Income (Loss) from Equity Method Investments USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxesPaid Income Taxes Paid USD 85,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 85,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 376,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxPaidForeignAfterRefundReceived IncomeTaxPaidForeignAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 26.37M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 0 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD -1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -28.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 1.14M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.05M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 320,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 261,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 3.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD -4.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -5.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap IncreaseDecreaseInDeferredIncomeTaxes Increase (Decrease) in Deferred Income Taxes USD 769,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap IncreaseDecreaseInReceivables Increase (Decrease) in Receivables USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 294,000 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0001725160-24-000107
us-gaap IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite-lived Intangible Assets (Excluding Goodwill) USD 0 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap InterestReceivable Interest Receivable USD 2.29M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 511,000 2020-09-30 2020 Q3 10-Q 2020-11-09 0001725160-20-000034
us-gaap InvestmentIncomeAmortizationOfPremium Investment Income, Amortization of Premium USD 17,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0001725160-22-000155
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 313,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-10 0001725160-21-000220
us-gaap Investments Investments USD 349.93M 2024-09-30 2024 Q3 10-Q 2024-11-12 0001725160-24-000173
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 48.05M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 14.98M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 7.45M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 8.11M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 8.11M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 7.93M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 7.76M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 1.82M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 11.34M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths Lessor, Operating Lease, Payment to be Received, Year One USD 655,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap Liabilities Liabilities USD 65.31M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 270.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LiabilitiesCurrent Liabilities, Current USD 32.36M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 500,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest USD 434.02M 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap MembersEquity Members' Equity USD 433.80M 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap MembersEquityAttributableToNoncontrollingInterest Members' Equity Attributable to Noncontrolling Interest USD 221,000 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap MinorityInterest Stockholders' Equity Attributable to Noncontrolling Interest USD 0 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 86.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 4.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -102.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -106.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap NetIncomeLossAttributableToNoncontrollingInterest Net Income (Loss) Attributable to Noncontrolling Interest USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap NoncontrollingInterestDecreaseFromDeconsolidation Noncontrolling Interest, Decrease from Deconsolidation USD 79,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD 18.42M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingExpenses Operating Expenses USD 113.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -113.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 6.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 3.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 36.71M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 4.27M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 32.44M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingLeasePayments Operating Lease, Payments USD 6.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 23.83M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.09 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 669,000 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap OtherAssetImpairmentCharges Other Asset Impairment Charges USD 4.14M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -691,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-09 0001725160-22-000200
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 14,000 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-17 0001725160-21-000129
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -691,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 500,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 44,000 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-17 0001725160-21-000129
us-gaap OtherReceivables Other Receivables USD 0 2023-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 9.98M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap PaymentsForRestructuring Payments for Restructuring USD 6.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 0 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0001725160-22-000155
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 5.70M 2026-08-17 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 175.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 34,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PrepaidExpenseAndOtherAssets Prepaid Expense and Other Assets USD 12.49M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 8.38M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PrepaidExpenseAndOtherAssetsNoncurrent Prepaid Expense and Other Assets, Noncurrent USD 4.11M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PrepaidInsurance Prepaid Insurance USD 578,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 86.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 707,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 180.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ProceedsFromMinorityShareholders Proceeds from Noncontrolling Interests USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ProceedsFromSaleOfEquitySecuritiesFvNi ProceedsFromSaleOfEquitySecuritiesFvNi USD 20.41M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 8,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -137.06M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 5.57M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 2.35M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ReclassificationsOfTemporaryToPermanentEquity Reclassifications of Temporary to Permanent Equity USD 155.93M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0001725160-23-000048
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 86.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RestrictedCash Restricted Cash USD 2.63M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 0 2023-12-31 2023 FY 10-K 2024-02-27 0001725160-24-000080
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 2.63M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RestrictedStockValueSharesIssuedNetOfTaxWithholdings Restricted Stock, Value, Shares Issued Net of Tax Withholdings USD -1.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RestructuringAndRelatedCostIncurredCost Restructuring and Related Cost, Incurred Cost USD 6.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.4 2025-01-28 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RestructuringCharges Restructuring Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RestructuringReserve Restructuring Reserve USD 0 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap RestructuringReserveCurrent Restructuring Reserve, Current USD 87,000 2025-09-30 2025 Q3 10-Q 2025-11-10 0001725160-25-000161
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.30B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Sale of Stock, Number of Shares Issued in Transaction shares 26.45M 2026-08-17 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 3.5 2026-08-17 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 9.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 0 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 5.87M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 17.52 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-26 0001725160-25-000067
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 3.59M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.48M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 15.11 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-09 0001725160-20-000034
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 16,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 12.26M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 11.02 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 16,000 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 12.26M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 11.02 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 0.94 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 21.17 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.64 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap SharePrice Share Price USD/shares 1.4 2025-12-12 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 204.89M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 204.89M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Stock Issued During Period, Shares, Restricted Stock Award, Forfeited shares 1,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-12 0001725160-21-000183
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 1.14M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 68,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap StockIssuedDuringPeriodValueConversionOfUnits Stock Issued During Period, Value, Conversion of Units USD 0 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 581,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 86.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 1,000 2022-01-01 2022-09-30 2023 Q3 10-Q 2023-11-06 0001725160-23-000196
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 126,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 9.98M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap SubleaseIncome Sublease Income USD 1.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap TemporaryEquityAggregateAmountOfRedemptionRequirement Temporary Equity, Aggregate Amount of Redemption Requirement USD 146.94M 2019-12-31 2020 FY 10-K 2021-03-25 0001725160-21-000075
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 155.93M 2020-03-31 2021 Q1 10-Q 2021-05-17 0001725160-21-000129
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 146.94M 2019-12-31 2020 FY 10-K 2021-03-25 0001725160-21-000075
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 0 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2021-12-31 2021 FY 10-K 2022-02-24 0001725160-22-000053
us-gaap TemporaryEquityStockIssuedDuringPeriodValueNewIssues Temporary Equity, Stock Issued During Period, Value, New Issues USD 14.23M 2020-01-01 2020-06-30 2021 Q2 10-Q 2021-08-12 0001725160-21-000183
us-gaap TradingSecuritiesDebt Debt Securities, Trading USD 204.90M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 16.03M 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 827,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 392,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 35.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-26 0001725160-26-000014
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 75.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 40.36M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-17 0001725160-21-000129
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 75.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001725160-26-000070

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →